Cargando…

Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis

AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zampiccoli, Emanuel, Barthelmes, Jens, Kreysing, Leonie, Nägele, Matthias P., Nebunu, Delia, Haider, Thomas, von Eckardstein, Arnold, Gerber, Bernhard, Schwotzer, Rahel, Ruschitzka, Frank, Sudano, Isabella, Flammer, Andreas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934987/
https://www.ncbi.nlm.nih.gov/pubmed/35060356
http://dx.doi.org/10.1002/ehf2.13792
_version_ 1784671949228605440
author Zampiccoli, Emanuel
Barthelmes, Jens
Kreysing, Leonie
Nägele, Matthias P.
Nebunu, Delia
Haider, Thomas
von Eckardstein, Arnold
Gerber, Bernhard
Schwotzer, Rahel
Ruschitzka, Frank
Sudano, Isabella
Flammer, Andreas J.
author_facet Zampiccoli, Emanuel
Barthelmes, Jens
Kreysing, Leonie
Nägele, Matthias P.
Nebunu, Delia
Haider, Thomas
von Eckardstein, Arnold
Gerber, Bernhard
Schwotzer, Rahel
Ruschitzka, Frank
Sudano, Isabella
Flammer, Andreas J.
author_sort Zampiccoli, Emanuel
collection PubMed
description AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro‐)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow‐mediated dilatation (FMD), and pulse‐wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND RESULTS: Flicker‐induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty‐three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light‐chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross‐sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log‐scaled troponin T (r = −0.49; P < 0.001), and N‐terminal pro‐B‐type natriuretic peptide (r = −0.51; P < 0.001)]. CONCLUSIONS: Retinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis.
format Online
Article
Text
id pubmed-8934987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89349872022-03-24 Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis Zampiccoli, Emanuel Barthelmes, Jens Kreysing, Leonie Nägele, Matthias P. Nebunu, Delia Haider, Thomas von Eckardstein, Arnold Gerber, Bernhard Schwotzer, Rahel Ruschitzka, Frank Sudano, Isabella Flammer, Andreas J. ESC Heart Fail Original Articles AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro‐)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow‐mediated dilatation (FMD), and pulse‐wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND RESULTS: Flicker‐induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty‐three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light‐chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross‐sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log‐scaled troponin T (r = −0.49; P < 0.001), and N‐terminal pro‐B‐type natriuretic peptide (r = −0.51; P < 0.001)]. CONCLUSIONS: Retinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis. John Wiley and Sons Inc. 2022-01-21 /pmc/articles/PMC8934987/ /pubmed/35060356 http://dx.doi.org/10.1002/ehf2.13792 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zampiccoli, Emanuel
Barthelmes, Jens
Kreysing, Leonie
Nägele, Matthias P.
Nebunu, Delia
Haider, Thomas
von Eckardstein, Arnold
Gerber, Bernhard
Schwotzer, Rahel
Ruschitzka, Frank
Sudano, Isabella
Flammer, Andreas J.
Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title_full Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title_fullStr Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title_full_unstemmed Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title_short Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
title_sort eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934987/
https://www.ncbi.nlm.nih.gov/pubmed/35060356
http://dx.doi.org/10.1002/ehf2.13792
work_keys_str_mv AT zampiccoliemanuel eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT barthelmesjens eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT kreysingleonie eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT nagelematthiasp eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT nebunudelia eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT haiderthomas eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT voneckardsteinarnold eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT gerberbernhard eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT schwotzerrahel eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT ruschitzkafrank eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT sudanoisabella eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis
AT flammerandreasj eyesonamyloidosismicrovascularretinaldysfunctionincardiacamyloidosis